Author: News Room

Company Corresponded with the FDA on an End of Phase 2 Meeting to Align on Phase 3 trial Design for Evaluation of Bezisterim in Early-stage Parkinson’s DiseaseCARSON CITY, Nev., Sept. 08, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced next stage of engagement with the Food and Drug Administration (FDA) to advance the Company’s Phase 3 development program evaluating bezisterim in Parkinson’s disease. “We are working closely with leading experts in Parkinson’s disease clinical development to finalize a Phase 3 trial design…

RESTON, Va., Sept. 08, 2026 (GLOBE NEWSWIRE) — Lightbridge Corporation (“Lightbridge” or the “Company”) (Nasdaq: LTBR), an advanced nuclear fuel technology company, today issued a letter to shareholders from Lightbridge’s Chairman & Chief Executive Officer, Seth Grae, following the Company’s selection for the U.S. Department of Energy’s Launch Pad INL Program. Dear Shareholders, Recently, we announced that Lightbridge has been selected to participate in the U.S. Department of Energy’s (DOE’s) Launch Pad program at Idaho National Laboratory (INL). This is an important milestone for our Company that can enable an accelerated pathway for the commercial deployment of Lightbridge Fuel™. In…

Five of seven RC holes return 7–29 m intervals at 0.53%–0.77% TREO to EOH; two deep five-metre intervals exceed 0.90% TREO and 0.23% MREOBELO HORIZONTE, Brazil and SINGAPORE, Sept. 08, 2026 (GLOBE NEWSWIRE) — Magnes Rare Earths (“Magnes”), a wholly owned subsidiary of Verde AgriTech Ltd. (TSX: NPK | OTCQX: VNPKF) (“Verde” or the “Company”), is pleased to report additional head-grade rare earth assay results from 146 drill holes totalling 1,299 assayed metres at the Minas Americas Global Alliance project (“Minas Americas” or the “Project”) in Minas Gerais, Brazil. The results comprise 139 completed auger holes totalling 1,027 m and…

LiveU is enabling AP to take global newsgathering to the next stage Bringing new intelligent connectivity and story-centric workflows HACKENSACK, N.J., Sept. 08, 2026 (GLOBE NEWSWIRE) — LiveU, the leader in live IP-video solutions, is enabling The Associated Press to take global newsgathering to the next stage with intelligent connectivity and story-centric workflows. The rollout connects the tools AP teams use in the field worldwide, helping them ensure the fastest turnaround for AP’s clients. AP will deploy LiveU Ingest, LiveU Transceivers and LiveU IQ connectivity across its global operations – including the industry’s largest deployment of LU900Q intelligent production units…

Two days of R44 AIRTRUCK flight operations put the unmanned variant of the Robinson R44 over an offshore-style deck, hosted by Aviation Academy of Louisiana R44 AIRTRUCK demonstration highlights showcasing remotely piloted flight operations, precision positioning, and offshore-style deck approaches at Acadiana Regional Airport in New Iberia, Louisiana. Robinson Unmanned R44 AIRTRUCK at Acadiana Regional Airport in New Iberia, Louisiana Robinson Unmanned R44 AIRTRUCK at Acadiana Regional Airport in New Iberia, Louisiana during demonstration of offshore cargo and resupply capabilities. Spectators at R44 AIRTRUCK Demo Spectators watch live demonstration of remotely piloted cargo delivery and offshore resupply with the Robinson…

VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) — Phoenix Metals Corp. (TSX: PCA) (“Phoenix Metals”, or the “Company”) is pleased to announce that the BC Ministry of Mining and Critical Minerals has issued an amended Exploration Permit MX-5-836 (the “Exploration Permit”) for the Greenwood project in south-central British Columbia (“Greenwood” or the “Project”). This amendment allows the Company to commence drilling of numerous targets within the top priority Phoenix Target Area. Following receipt of the Exploration Permit, Phoenix awarded a 51,500-metre drill contract in order to accelerate the exploration of the top priority targets within the Phoenix Target Area,…

Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in people with HAE Type 1 or Type 2All secondary efficacy endpoints met with statistical significanceWell-tolerated safety profile of deucrictibant XR demonstratedConference call and webcast today at 8:00 a.m. EDT ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema (AE-BK), such as hereditary angioedema (HAE) and…

An American litigation funder is threatening to call in more than $100 million in alleged debt from Alberta separatist leader and lawyer Jeffrey Rath and his firm, Global News has learned. Delaware-based Diriba Investments LLC alleges in court documents that Rath and his professional corporation, RathPC, defaulted two years ago on a financing agreement tied to First Nations and COVID-19 litigation cases — a debt the lender now says totals nearly $109 million, plus interest and costs.Rath and his corporation now face pressure on two fronts. As Global News reported last month, two former First Nations clients have filed separate…

Nova Minerals Corp A time lapse video of Nova’s antimony processing plant equipment being unloaded at Port MacKenzie Nova Minerals Corp Barge loaded with Nova’s antimony processing equipment arriving at Port MacKenzie Nova Minerals Corp Barge unloading at Port MacKenzie Nova Minerals Corp 40ft shipping containers loaded onto trucks for the short haul to the Nova Minerals antimony processing plant site Nova Minerals Corp Aerial view of Nova Minerals antimony processing plant site which has been prepared ready for construction Nova Minerals Corp Aerial view of Port MacKenzie highlighting the site for Nova’s antimony processing plant Anchorage, Alaska, Sept. 08,…

LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United Kingdom, with a submission to the European Medicines Agency planned for later this monthSAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) — Biosplice Therapeutics, Inc. (“Biosplice”), a late-stage biopharmaceutical company developing lorecivivint (“LOR”), a first-in-class small-molecule inhibitor of CLK/DYRK kinases, for the treatment of knee osteoarthritis (“OA”), announced today that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (“MHRA”) has determined Biosplice’s application for approval of LOR to be complete and valid. Acceptance of the application starts the MHRA’s formal review timetable…